Investors boosted stakes in pharmaceutical giant Novo Nordisk, rated "Buy" with a $144.50 target price.

Blackhawk Capital Partners and other firms increased their stakes in Novo Nordisk A/S during the third quarter, reflecting growing investor interest. The pharmaceutical company, known for diabetes and rare disease treatments, has seen a mix of analyst ratings, currently averaging a "Buy" with a target price of $144.50. Novo Nordisk's stock has ranged between $94.73 and $148.15 over the past year, with a market cap of $472.51 billion.

November 21, 2024
4 Articles

Further Reading